VIDAC PHARMA HOLDING PLC
Commented by Fabian Lorenz on February 13th, 2025 | 07:10 CET
ACQUISITION?! Renk, BioNTech, and Biotech Highflyer Vidac Pharma
Is Renk about to be taken over? Quite possible. The Company, known for its transmissions for the Leopard tank, has a new major shareholder. And it turns out to be none other than KNDS – the maker of the Leopard 2 tank. The Renk share price reacted with a jump of 10%. Is there more to come? Vidac Pharma is also frequently mentioned as a potential takeover candidate. Like BMW, the Company is working on a "new class". But in this case, it is to save human lives. To this end, last year's biotech highflyer aims to revolutionize cancer treatment. Experts believe that a multiplication of the share price is possible. BioNTech is also fighting cancer. In addition to its own research, the German company is strategically focusing on acquisitions. Another one has just been completed. What is next?
Read
Commented by Juliane Zielonka on January 31st, 2025 | 06:55 CET
Vidac Pharma, Bayer AG, Novo Nordisk: Three companies that will shape the pharmaceutical landscape in 2025
The pharmaceutical industry is again demonstrating its market power between innovation and risk: Vidac Pharma reports a milestone in colorectal cancer therapy with VDA1275. The combination of the active ingredient with a chemotherapeutic agent achieves a 38.9% tumor reduction in preclinical studies. This synergy effect raises hope for gentler chemotherapy treatments and more innovative approaches. Bayer AG is making waves at the JP Morgan Health Conference with its pharmaceutical pipeline: the prostate cancer drug Nubeqa™ achieves blockbuster status with revenue of EUR 1 billion. In women's health, the first non-hormonal therapy for menopausal symptoms is expected to reach the US market as early as 2025. Novo Nordisk, on the other hand, is threatened with a class-action lawsuit in the billion-dollar market for obesity drugs: the REDEFINE-1 study on the promising drug CagriSema revealed weaknesses in the study design. After the results were made public, the share price fell by 18%. While Vidac Pharma and Bayer impress with precise study results, the Novo Nordisk case shows the fragility of methodological fuzziness. The details.
Read
Commented by Armin Schulz on January 22nd, 2025 | 07:00 CET
Evotec, Vidac Pharma, BioNTech – Profiting from the fight against cancer
It has been clear for some time that cancer can affect anyone, and not just since King Charles and Princess Kate made their battles with cancer public. The market is growing, and today, revenues in this area are already in the billions. This is driven by an aging population and increasingly unhealthy lifestyles. The margins for manufacturers of cancer drugs are often in the high double-digit percentage range. It is no wonder that companies are focusing on the fight against cancer. Developing a medication that reliably defeats the disease could result in a genuine blockbuster. In 2023, around USD 223 billion was spent on cancer drugs worldwide. We are looking at three companies striving to cure cancer and claim their share of this lucrative market.
Read
Commented by Stefan Feulner on January 14th, 2025 | 07:55 CET
Qiagen, Vidac Pharma, and Bayer with groundbreaking news
In the years to come, biotechnology will play a central role in solving global challenges. From the development of innovative therapies to sustainable agriculture and biobased industries, biotechnology combines science and technology to make the world more sustainable and efficient. As a driver of growth and innovation, it offers enormous opportunities for companies and investors who want to actively shape the future.
Read
Commented by André Will-Laudien on January 6th, 2025 | 07:00 CET
Biotech-Rally 2025: Evotec, BioNTech, Vidac Pharma, Pfizer and Bayer are on the buy list
For two years, there was almost no movement in the biotech sector. Not even the trend of falling interest rates that began in 2024 could persuade investors to make larger investments. Meanwhile, AI and high-tech stocks continued to perform well, driving the Nasdaq 100 index up by over 30%. However, in the last quarter of 2024, some bombed-out life sciences stocks saw significant markups, and new takeover rumours also began circulating. Whether the sentiment can continue to rise in the coming weeks is something we will explore further. Let's take a closer look at our top picks for 2025.
Read
Commented by Juliane Zielonka on December 23rd, 2024 | 11:55 CET
Pharma stocks in focus: Setback for Novo Nordisk, spot-on performance for Vidac Pharma and Bayer
Updates from the pharmaceutical and biotech sector for investors: The Danish company Novo Nordisk is experiencing a setback in the development of its new weight loss drug, CagriSema. Vidac Pharma and Bayer, on the other hand, have positive news to report. The biotech company has received an extension of patent protection for its innovative cancer drugs from the US Patent Office, presenting a unique opportunity for investors. Bayer is also celebrating a success: the higher-dose version of the eye drug Eylea has delivered convincing results in the latest study. This means that in the future, patients will require less frequent injections into the eye. We take a closer look at the developments.
Read
Commented by Fabian Lorenz on December 19th, 2024 | 07:00 CET
Evotec, Rheinmetall, Vidac Pharma: Buy recommendation, cancer revolution, or price collapse?
Analysts see significant potential for multiplication with Vidac Pharma's stock. It has already been one of the standout performers in the biotech sector in the second half of the year. The Company aims to revolutionize cancer treatment and has published the next top news. Analysts also see further price potential for Rheinmetall. However, shareholders should brace themselves for a possible significant correction in the share price of Germany's largest defense contractor. By contrast, opinions on Evotec remain divided. Is the share price at risk of halving again after a year to forget? Or is now the time to buy in?
Read
Commented by André Will-Laudien on December 10th, 2024 | 07:00 CET
Biotech Acquisitions in 2025: Several 100% Gains Expected – Evotec, Vidac Pharma, BioNTech, and Pfizer
There have already been two attempts, but the story continues! Evotec speculators were confronted with a rumor mill and a takeover bid in November. This is what happens when a stock plummets and languishes for a long time. The management wisely rejected Halozyme's undervalued offer, and thus, the bidding war for the Hamburg-based company began anew. In the biotech sector, eyes should now be on the future, as the first movements have already taken place. In our stock selection, there are three outliers with price increases of more than 30% in the last 3 months. However, the big moves will only take place in 2025. Here is an analytical look at a long-neglected sector.
Read
Commented by Armin Schulz on December 2nd, 2024 | 07:20 CET
Evotec, Vidac Pharma, BioNTech – Cancer research: The gold mine in the portfolio
Investing in publicly traded companies active in oncology research offers promising returns and long-term stability. The oncology market is one of the fastest-growing sectors in healthcare and benefits from an ever-increasing demand for innovative and personalized cancer therapies. Advances such as CAR-T cell therapies and antibody-drug conjugates are revolutionizing treatment options and creating new opportunities for companies and investors. At the same time, the sector is characterized by a low dependence on economic fluctuations and a high level of dynamism in mergers and acquisitions. With long-term trends such as an aging population, this market offers solid prospects for investors. We take a look at three promising companies.
Read
Commented by Fabian Lorenz on November 18th, 2024 | 07:00 CET
Takeover speculation and momentum: BioNTech, Rheinmetall, Vidac Pharma
BioNTech aims to strengthen its cancer-fighting pipeline by acquiring the Chinese biotech firm Biotheus. The Mainz-based company is laying out up to USD 950 million for the company, which specializes in the development of therapies for cancer and autoimmune diseases. This is the latest example of takeovers in the cancer sector. Vidac Pharma, with a market capitalization of just over EUR 30 million, appears to be favorably valued. Analysts share this view, as Vidac is working on a revolutionary cancer therapy. While Vidac's share price jumped in the second half of the year, Rheinmetall consolidated. Will the defense stock be able to break out with the tailwind from Trump?
Read